Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169572 per QALY and exenatide with $278935 per QALY as second-line treatment in adult diabetics in the USA

    Research output: Contribution to journalReview article

    2 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)40-41
    JournalEvidence - Based Medicine (English Edition): for primary care and internal medicine
    Issue number2
    Publication statusPublished - 2010

    Cite this